title: Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.
abstract: The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan ; Department of Urology, Rinku General Medical Center, Osaka, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishizawa
authors.affiliation: Department of Urology, Kinan Hospital, Wakayama, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inagaki
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Akinori
authors.initials: A
authors.lastname: Iba
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Kazuro
authors.initials: K
authors.lastname: Kikkawa
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Kodama
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Nagahide
authors.initials: N
authors.lastname: Matsumura
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kohjimoto
authors.affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Hara
keywords: Androgen deprivation therapy; Bone mineral density; Combined androgen blockade; Prostate cancer; Zoledronic acid